To further determine whether the overexpression of BAIAP2 could prevent CMS-induced depression-like behavior and concomitant cognitive impairment in vivo, bilateral hippocampal stereotactic injection of AAV-BAIAP2 or AAV-CON was performed once 2 weeks before the administration of CMS (Figure 4A). Here, BAIAP2 is linked to depressive disorder.